IRIS
LAUDICELLA, Riccardo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.984
NA - Nord America 2.603
AS - Asia 1.842
SA - Sud America 669
AF - Africa 53
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.155
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.517
RU - Federazione Russa 1.179
SG - Singapore 876
BR - Brasile 580
IE - Irlanda 421
SE - Svezia 390
IT - Italia 381
CN - Cina 344
HK - Hong Kong 280
DE - Germania 161
VN - Vietnam 104
PL - Polonia 85
GB - Regno Unito 76
IN - India 72
FR - Francia 69
FI - Finlandia 51
CA - Canada 42
AR - Argentina 37
AT - Austria 31
MX - Messico 31
ZA - Sudafrica 26
JP - Giappone 24
BE - Belgio 23
LT - Lituania 23
NL - Olanda 21
ES - Italia 19
TR - Turchia 19
ID - Indonesia 18
IQ - Iraq 13
BD - Bangladesh 11
IR - Iran 11
VE - Venezuela 11
AE - Emirati Arabi Uniti 10
EC - Ecuador 10
UA - Ucraina 10
MA - Marocco 9
PE - Perù 9
UZ - Uzbekistan 9
PY - Paraguay 8
AZ - Azerbaigian 7
CZ - Repubblica Ceca 7
IL - Israele 7
CO - Colombia 6
GE - Georgia 5
PK - Pakistan 5
CH - Svizzera 4
CL - Cile 4
KW - Kuwait 4
NO - Norvegia 4
PT - Portogallo 4
BG - Bulgaria 3
BY - Bielorussia 3
EG - Egitto 3
GR - Grecia 3
JM - Giamaica 3
JO - Giordania 3
KE - Kenya 3
LA - Repubblica Popolare Democratica del Laos 3
LV - Lettonia 3
PA - Panama 3
PH - Filippine 3
SA - Arabia Saudita 3
UY - Uruguay 3
AL - Albania 2
AU - Australia 2
BW - Botswana 2
CI - Costa d'Avorio 2
DO - Repubblica Dominicana 2
HU - Ungheria 2
LU - Lussemburgo 2
PR - Porto Rico 2
RO - Romania 2
SN - Senegal 2
TN - Tunisia 2
AM - Armenia 1
AO - Angola 1
BO - Bolivia 1
DK - Danimarca 1
DM - Dominica 1
DZ - Algeria 1
EU - Europa 1
GD - Grenada 1
HN - Honduras 1
HR - Croazia 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LK - Sri Lanka 1
MD - Moldavia 1
MK - Macedonia 1
MN - Mongolia 1
MU - Mauritius 1
NG - Nigeria 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TH - Thailandia 1
TW - Taiwan 1
Totale 8.155
Salva come PNG Salva come JPEG
Città #
Moscow 634
Ashburn 449
Dublin 419
Chandler 413
Singapore 398
Nyköping 288
Hong Kong 280
Dallas 262
Beijing 137
Messina 113
Los Angeles 110
The Dalles 89
Warsaw 78
Princeton 74
Munich 70
Medford 61
São Paulo 53
New York 40
Bremen 37
Ho Chi Minh City 36
Des Moines 35
Redondo Beach 34
Buffalo 32
Rome 29
Hyderabad 27
Helsinki 26
Brussels 23
Nuremberg 23
Hanoi 21
Santa Clara 20
Stockholm 20
Jacksonville 19
Palermo 19
Johannesburg 18
Montreal 18
Dearborn 17
Frankfurt am Main 17
Seattle 17
Turku 17
London 16
Orem 16
Vienna 16
Denver 15
Mumbai 14
Tianjin 14
Tokyo 14
Atlanta 13
Boston 13
Jakarta 13
Jinan 13
Porto Alegre 13
Rio de Janeiro 13
Boardman 12
Brasília 12
Brooklyn 12
Poplar 12
Campinas 11
Curitiba 11
Ann Arbor 10
Kameido 10
Mexico City 10
Nanjing 10
Pune 10
Amsterdam 9
Belo Horizonte 9
Bexley 9
Chennai 9
Genoa 9
Milan 9
Phoenix 9
Tashkent 9
Toronto 9
Dong Ket 8
Lappeenranta 8
San Francisco 8
Ankara 7
Baku 7
Cagliari 7
Chicago 7
Hangzhou 7
Houston 7
Nanchang 7
São José do Rio Preto 7
Wilmington 7
Betim 6
Biên Hòa 6
Charlotte 6
Haiphong 6
Lima 6
Ottawa 6
Redwood City 6
Shenyang 6
Tel Aviv 6
West Jordan 6
Wroclaw 6
Barcellona Pozzo di Gotto 5
Catania 5
Düsseldorf 5
Feira de Santana 5
Fortaleza 5
Totale 5.035
Salva come PNG Salva come JPEG
Nome #
Artificial intelligence in molecular imaging: from machine to deep learning 168
[68 Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [177 Lu]DOTATOC PRRT: The “Theragnomics” Concept 162
PRRT Retreatments: Renal Function Evaluation 158
18F-FDG PET/CT Imaging of Immune Checkpoint Inhibitor-Related "Retroperitoneal Panniculitis" 158
Peptide Receptor Radionuclide Therapy and Somatostatin 'cold' Analogues Therapy in the Treatment of GEP-NET Patients: Our Center’ Experience 157
223RA-dichloride use in patients affected by bone metastases from castration-resistant prostate cancer: single centre experience 149
Prognostic Validity of Dual Tracer PET/CT in the PRRT Enrollment of GEP-NET Patients 147
Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience 146
Complete Response in a Pancreatic Nen with Liver Metastasis after PRRT in association with Lanreotide Autogel/depot: Design of the Prelude Study 142
18F-FACBC in prostate cancer: A systematic review and meta-analysis 141
A Single Centre Experience with 223-Radium-Dichloride ((RaCl2)-Ra-223) Therapy 139
Effectiveness, safety and haematological toxicity of 223Ra-Cl2: a single centre experience 139
Clinico-laboratory response and haematological toxicity in patients undergoing therapy with 223RA-dichloride 138
Safety, effectiveness and haematological toxicity of 223Radichloride: a single Centre experience 135
Prognostic and diagnostic value of [18F]FDG-PET/CT in restaging patients with small cell lung carcinoma: an Italian multicenter study 130
Diagnosis of cardiac amyloid transthyretin (ATTR) amyloidosis by early (soft tissue) phase [99mTc]Tc-DPD whole body scan: comparison with late (bone) phase imaging 129
COVID-19 Surface Persistence: A Recent Data Summary and Its Importance for Medical and Dental Settings 127
Dual Time-Point FET-PET/CT in Glioma Patients: a Single-Centre Preliminary Experience 126
Complete response in a pancreatic NEN with liver metastasis after PRRT in association with lanreotide autogel/depot 124
PRRT retreatments: renal function evaluation 121
18F-FDG PET/MR Refines Evaluation in Newly Diagnosed Metastatic Urethral Adenocarcinoma 121
Renal Function Evaluation in PRRT Retreatments 119
Differentiating malignant from benign thyroid nodules with indeterminate cytology by 99mTc-MIBI scan: A new quantitative method for improving diagnostic accuracy 118
Prognostic Validity of Dual Tracer PET/CT In The PRRT Enrollment of GEP-NET Patients 116
Comparing radioiodine abdominal absorbed dose in differentiated thyroid cancer patients undergone thyroid remnant ablation in either levo-thyroxine withdrawal or after rhtsh stimulation 110
[177Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective 107
Is dual tracer PET/CT a prognostic biomarker in the PRRT enrollment of GEP-NET patients? 106
Unconventional non-amino acidic PET radiotracers for molecular imaging in gliomas 105
Peptide Receptor Radionuclide Therapy of Pulmonary Neuroendocrine Neoplasms: a Single-Centre Experience 105
Serial scanning with 99mTc-3, 3-diphosphono-1, 2-propanodicarboxylic acid (99mTc-DPD) for early detection of cardiac amyloid deposition and prediction of clinical worsening in subjects carrying a transthyretin gene mutation 104
The additional value of 18F-FDG PET and MRI in patients with glioma: A review of the literature from 2015 to 2020 101
Artifcial intelligence applications in SSTR targeted PET/CT images: prediction of response assessment in GEP-NETs undergoing PRRT with [177Lu]DOTATOC 101
Radiomics Analysis of Brain [18 F]FDG PET/CT to Predict Alzheimer’s Disease in Patients with Amyloid PET Positivity: A Preliminary Report on the Application of SPM Cortical Segmentation, Pyradiomics and Machine-Learning Analysis 99
Peptide receptor radionuclide therapy (PRRT) in patients with giant aggressive pituitary tumors: experience of an Italian referral center and review of literature 97
The utility of dual time-point FET-PET/CT in recurrence assessment of glioma patients 96
Subcutaneous Uptake on [18F]Florbetaben PET/CT: a Case Report of Possible Amyloid-Beta Immune-Reactivity After COVID-19 Vaccination 95
Correction to: 18F-FMISO PET imaging: insights over MRI in patients with glioma (Clinical and Translational Imaging, (2020), 8, 1, (3-10), 10.1007/s40336-019-00353-0) 94
PET/MR in neuro-oncology: is it ready for prime-time? 91
Artificial neural networks in cardiovascular diseases and its potential for clinical application in molecular imaging 88
Artificial intelligence applications in 68Ga-DOTA PETICT images: Prediction of response assessment in GEP-NETs undergoing PRRT with 177Lu-DOTATOC 87
Artificial Intelligence Applications on Restaging [18F]FDG PET/CT in Metastatic Colorectal Cancer: A Preliminary Report of Morpho-Functional Radiomics Classification for Prediction of Disease Outcome 85
Sars-cov-2 persistence: data summary up to q2 2020 85
PSMA and Choline PET for the Assessment of Response to Therapy and Survival Outcomes in Prostate Cancer Patients: A Systematic Review from the Literature 84
68Ga-PSMA-11 PET/MRI versus multiparametric MRI in men referred for prostate biopsy: primary tumour localization and interreader agreement 83
[18F] Fluorothymidine Positron Emission Tomography Imaging in Primary Brain Tumours: A Systematic Review 82
Non-invasive cardiac imaging in patients with systemic amyloidosis: a practical approach with emphasis on clinical contribution of bone-seeking radiotracers 82
Prevalence of interstitial pneumonia suggestive of COVID-19 at 18F-FDG PET/CT in oncological asymptomatic patients in a high prevalence country during pandemic period: a national multi-centric retrospective study 81
Molecular imaging of pancreatic neoplasms 80
Preliminary Findings of the Role of FAPi in Prostate Cancer Theranostics 80
Advantages of SiPM-based digital PET/CT technology in nuclear medicine clinical practice: a systematic review– part 2 78
Emerging applications of imaging in glioma: focus on PET/MRI and radiomics 76
Correction to: Diagnosis of cardiac amyloid transthyretin (ATTR) amyloidosis by early (soft tissue) phase [99mTc]Tc-DPD whole body scan: comparison with late (bone) phase imaging 75
Undetectable or low (< 1 ng/ml) postsurgical thyroglobulin values do not rule out metastases in early stage differentiated thyroid cancer patients 75
Malignant cutaneous melanoma: Updates in PET imaging 73
Prognostic insights of molecular imaging in cardiac sarcoidosis 72
Combined use of peptide receptor radionuclide therapy and metronomic chemotherapy in neuroendocrine tumors: a possible choice driven by nuclear medicine molecular imaging 71
The prognostic power of 18F-FDG PET/CT extends to estimating systemic treatment response duration in metastatic castration-resistant prostate cancer (mCRPC) patients 68
Imaging gastrin-releasing peptide receptors (GRPRs) in prostate cancer 67
FAPi-Based Agents in Thyroid Cancer: A New Step towards Diagnosis and Therapy? A Systematic Review of the Literature 66
Infiltrative growth pattern of prostate cancer is associated with lower uptake on PSMA PET and reduced diffusion restriction on mpMRI 64
From bench to bedside: highlights from the International Dialogue on Ovarian Cancer 63
Head-to-Head Comparison of FDG and Radiolabeled FAPI PET: A Systematic Review of the Literature 62
[11C]Choline PET/CT in a Patient with Prostate Cancer Biochemical Recurrence Showing Two Suspicious Findings in the Breast and Liver 62
Prostate Cancer Biochemical Recurrence Resulted Negative on [68Ga]Ga-PSMA-11 but Positive on [18F]Fluoromethylcholine PET/CT 59
Response prediction to PRRT in progressing and metastatic GEP-NET undergoing restaging 68Ga-DOTA PETICT: A preliminary multicenter radiomics study 59
The Utility of Conventional Amino Acid PET Radiotracers in the Evaluation of Glioma Recurrence Also in Comparison with MRI 59
A Multimodal Clinical Approach for the Treatment of Bone Metastases in Solid Tumors 58
An Overview of In Vitro Assays of 64Cu-, 68Ga-, 125I-, and 99mTc-Labelled Radiopharmaceuticals Using Radiometric Counters in the Era of Radiotheranostics 57
Prostate-Specific Membrane Antigen Positron Emission Tomography Oncological Applications beyond Prostate Cancer in Comparison to Other Radiopharmaceuticals 57
[18F]FDG PET/CT criteria for treatment response assessment: EORTC and beyond 55
PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score 54
PET Imaging in Gliomas: Clinical Principles and Synergies with MRI 51
Choline PET/CT features to predict survival outcome in high-risk prostate cancer restaging: a preliminary machine-learning radiomics study 51
Radiomics and artificial intelligence in prostate cancer: new tools for molecular hybrid imaging and theragnostics 51
Advantages of SiPM-based digital PET/CT technology in nuclear medicine clinical practice: a systematic review—Part 1 oncological setting 50
State of the art of 18F-FDG PET/CT application in inflammation and infection: a guide for image acquisition and interpretation 49
A Review of Advances in Molecular Imaging of Rheumatoid Arthritis: From In Vitro to Clinic Applications Using Radiolabeled Targeting Vectors with Technetium-99m 48
Recombinant human thyrotropin (rhTSH) versus Levo-thyroxine withdrawal in radioiodine therapy of differentiated thyroid cancer patients: differences in abdominal absorbed dose 48
Combined forced diuresis and late acquisition on [68Ga]Ga-PSMA-11 PET/CT for biochemical recurrent prostate cancer: a clinical practice-oriented study 47
Applications of Artificial Intelligence and Radiomics in Molecular Hybrid Imaging and Theragnostics for Neuro-Endocrine Neoplasms (NENs) 46
Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review 44
[18F]PSMA‑1007 PET/CT‑based radiomics may help enhance the interpretation of bone focal uptakes in hormone‑sensitive prostate cancer patients 43
Monitoring of cardiac transthyretin amyloid load by [Tc-99m]DPD scintigraphy: is it the end of the semi-quantitative evaluation? 43
ChatGPT in nuclear medicine and radiology: lights and shadows in the AI bionetwork 40
Correction: PSMA‑positive prostatic volume prediction with deep learning based on T2‑weighted MRI 39
Reply to Perera Molligoda Arachchige AS [1] 39
PSMA-positive prostatic volume prediction with deep learning based on T2-weighted MRI 37
Quantitative imaging parameters to predict the local staging of prostate cancer in intermediate- to high-risk patients 37
Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding [68Ga]Ga-PSMA-11 PET scans of primary prostate cancer 37
Is There a Role of Interim PSMA PET in Chemotherapy of Prostate Cancer? 37
The role of PET radiomic features in prostate cancer: a systematic review 36
Can We Predict Skeletal Lesion on Bone Scan Based on Quantitative PSMA PET/CT Features? 35
Artificial intelligence in molecular imaging: from machine to deep learning 32
The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers 31
Unspecic bone uptakes in PSMA PET for prostate cancer: why do they matter? 31
[68Ga]Ga-PSMA Versus [18F]PSMA Positron Emission Tomography/Computed Tomography in the Staging of Primary and Recurrent Prostate Cancer. A Systematic Review of the Literature 31
The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer 30
Artificial Intelligence and Statistical Models for the Prediction of Radiotherapy Toxicity in Prostate Cancer: A Systematic Review 30
The Role of Theragnostics in Breast Cancer: A Systematic Review of the Last 12 Years 29
Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding ­ [68Ga] Ga‑PSMA‑11 PET scans of primary prostate cancer 23
Totale 8.213
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.772
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.772
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021137 0 0 0 0 0 13 12 14 43 27 17 11
2021/2022464 6 30 4 22 31 13 27 34 6 54 35 202
2022/20231.387 119 196 70 107 91 140 17 89 482 16 36 24
2023/2024369 41 39 22 33 43 50 13 31 9 32 16 40
2024/20252.168 12 59 45 75 153 64 154 317 510 184 287 308
2025/20263.583 450 366 384 424 556 1.403 0 0 0 0 0 0
Totale 8.375